The XABG restorative coronary artery bypass graft (CABG) by Xeltis will feature in a session on the future of vascular therapeutic at the European Symposium on Vascular Biomaterials (ESVB) meeting.
In his presentation “Xeltis: towards grafts from supramolecular materials”, CTO and Co-Founder Martijn Cox will provide an update on the company’s revolutionary restorative synthetic graft and on its progression towards clinical phase. XABG has to date shown unprecedented patency results in preclinical trials. The session will take place on November 6 at 8.30am CET.
“It is an incredibly exciting phase for our company, which may open up new avenues for the treatment of patients,” Martijn explained. “XABG may for the first time potentially spare vein harvesting to patients undertaking CABG surgery, which explains the interest in our technology from biomaterials and vascular experts.”
ESVB is organized every other year by GEPROVAS, a non-profit organization promoting transdisciplinary research in the field of cardiovascular biomaterials. Taking place in Strasbourg from 4 to 6 November, the meeting is the largest event in Europe dedicated to biomaterials applied to vascular and endovascular surgery.
